Nvidia stock price rises today as China signals H200 AI chip orders could restart (NVDA)
23 January 2026
2 mins read

Nvidia stock price rises today as China signals H200 AI chip orders could restart (NVDA)

New York, January 23, 2026, 09:36 AM ET — Regular session underway.

  • Nvidia shares climbed in early trading following reports that Chinese regulators instructed leading tech companies to get ready to order its H200 AI chips
  • The shift unfolds amid investor concerns over export-policy risks and the Federal Reserve’s decision looming next week
  • Nvidia will release its quarterly earnings on Feb. 25

NVIDIA Corp shares climbed on Friday following a report that Chinese authorities instructed Alibaba, Tencent, and ByteDance to start preparing orders for Nvidia’s H200 AI chips. Investors saw this as a sign of progress toward reopening the crucial Chinese market. The stock gained 0.8% to $184.84, after earlier jumping nearly 3%. 1

This report is significant because Nvidia’s sales in China have been unpredictable, caught in the crossfire of U.S. export restrictions and Beijing’s scrutiny over advanced chip destinations. Traders want something solid—an order, a confirmed shipment date—anything that shifts “maybe” into actual revenue.

The tape was unsettled as chip stocks showed a mixed picture, with Intel slipping on a disappointing outlook. Investors brace for a busy week loaded with earnings reports and a Fed meeting. “Guidance now is more critical than ever,” noted Peter Cardillo, chief market economist at Spartan Capital Securities. 2

Earlier this month, the Trump administration formally approved China-bound H200 sales, but with strings attached: third-party testing before export and caps tied to U.S. sales, per the new rules. Nvidia hailed the regulation as “a thoughtful balance that is great for America.” Seaport Research’s Jay Goldberg, however, dismissed it as “a Band-Aid,” cautioning that enforcing these measures could get tricky. 3

Beijing’s position remains unclear. Nvidia CEO Jensen Huang is set to visit China in late January, coinciding with Lunar New Year festivities, Bloomberg reported earlier this week. The trip aims to help Nvidia regain ground in the Chinese market; the company declined to comment. 4

Still, the downside remains a real risk. That initial approval might hit a wall, Washington could crank up the pressure, and new restrictions could tighten around Chinese buyers—limiting who accesses the chips and how they use them.

The next clear trigger is in Washington, not Santa Clara. The Fed convenes Jan. 27-28, with its policy call set for 2 p.m. ET on Jan. 28, then a press briefing at 2:30 p.m. 5

Next week’s earnings season will put the broader “AI trade” under the microscope. Around 20% of the S&P 500 is set to report, and investors are eager to see AI spending translate into actual profits, not just capital expenditures. “At the end of the day, earnings are the driver,” said Chris Galipeau, senior market strategist at Franklin Templeton. 6

Nvidia’s next key date is Feb. 25, when it’s set to release its fourth-quarter fiscal 2026 results, per the company’s investor calendar. 7

Traders will be closely tracking if “prepare orders” shift into actual purchase orders and if clearer timing on shipments to China comes through. The Fed’s decision on Jan. 28 looms as the immediate challenge, with Nvidia’s update on Feb. 25 set to be the next major event for NVDA.

Stock Market Today

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
New York, Feb 7, 2026, 09:35 EST — Market closed. Roivant Sciences Ltd shares leapt on Friday after the company reported positive mid-stage results for its immune-modulating drug brepocitinib in a rare skin disease, and paired the readout with its quarterly financial update. The Nasdaq-listed stock closed up 22.4% at $25.82, leaving traders to gauge whether the move has legs when U.S. markets reopen on Monday, Feb. 9. It matters because Roivant is trying to turn a late-stage pipeline into approvals, and the market has been quick to reward biotechs that can show clean efficacy in controlled trials. The company
Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
AMD stock jumps 8% in chip rebound — what investors are watching before Monday

AMD stock jumps 8% in chip rebound — what investors are watching before Monday

7 February 2026
AMD shares jumped 8.2% to $208.44 Friday, trading on heavy volume as chip stocks rebounded and the Dow closed above 50,000 for the first time. The Philadelphia Semiconductor Index rose 5.7% after Amazon’s AI spending plans lifted sector estimates. Nvidia’s CEO cited surging AI chip demand. AMD’s rally followed a weak revenue outlook earlier in the week.
Tesla stock jumps on Austin robotaxi step as Musk talks Optimus timeline ahead of earnings
Previous Story

Tesla stock jumps on Austin robotaxi step as Musk talks Optimus timeline ahead of earnings

Microsoft stock rises after Microsoft 365 outage clears as MSFT heads into earnings week
Next Story

Microsoft stock rises after Microsoft 365 outage clears as MSFT heads into earnings week

Go toTop